Health plans face challenges in risk arrangements for orphan drugs, but increasing competition may open doors for innovative ...

T O APPRECIATE the dilemmas the Food and Drug Administration (FDA) faces when it reviews new drugs targeting rare diseases, ...

The Drug Discovery Services Companies Quadrant provides an in-depth analysis of the drug discovery services market, highlighting key players, technological advancements, and trends. Conducted by ...

Beam Therapeutics' said the Food and Drug Administration granted generative medicine advanced therapy designation to its sickle cell disease treatment BEAM-101.

Most favored nation pricing would unintentionally put these heroes, and generations of future service members, in harm’s way.

Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer, during an oral presentation at the 2025 ...

Net loss per share (GAAP) of $(0.52) improved over the $(0.68) loss expected. Research and development expenses (GAAP) dropped to $1.8 million from $4.9 million in Q2 2024. Regulatory progress for ...

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- U ...

In August 2025, Dren Bio announced a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics ...

More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for ...

Hatteras was founded in 2000 with the closing of Hatteras Venture Partners I, a seed-stage venture fund with $2.93 million in capital. Today, the firm is focused on seed- and early stage companies in ...